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Background: Polycystic kidney diseases (PKD) are a group of monogenic disorders that are inherited dominantly
(autosomal dominant PKD; ADPKD) or recessively, including, autosomal recessive PKD (ARPKD). A number of
recessive, syndromic disorders also involve PKD but have a range of pleiotropic phenotypes beyond the kidney, and
are enriched in consanguineous families.
Case presentation: We describe here a consanguineous Iranian pedigree in which PKD was diagnosed in four
generations, but also included cases with additional abnormalities, including mental retardation. We employed
molecular screening to reveal the etiology of the PKD. Since the PKD seemed to be dominantly inherited,
molecular diagnostics was performed by direct sequencing of the ADPKD genes, PKD1 and PKD2. Clinical and
imaging data was collected on family members. The sequence analysis revealed a PKD2 single base-pair deletion,
c.1142delG, and segregation was demonstrated in 16 PKD patients from different branches of the family. In keeping
with other reports, the PKD2 phenotype in this family was overall mild, and characterized by conserved kidney
function, although 12 cases had some evidence of renal insufficiency. Several younger mutation carriers had
borderline or no clinical characteristics of ADPKD, while a patient that required a renal transplant at 14 y did not
have the PKD2 mutation.
Conclusions: The molecular analysis of an Iranian family showed that the PKD was due to a PKD2 mutation. The
identification of the causative mutation allowed an accurate diagnosis in a number of individuals with equivocal
imaging data. Consequently, these patients could be followed appropriately as at-risk individuals. In addition, the
PKD2 diagnosis ruled out a syndromic form of PKD as the cause of the additional phenotypes in the family.
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Polycystic kidney diseases (PKD) are a group of mono-
genic disorders characterized by cyst development in the
kidney, but also often have extrarenal manifestations [1].
This group of disorders has been linked to defects in the
functioning of primary cilia and therefore are termed
ciliopathies [2]. The most common form of the disease
(incidence 1/500-1000) is autosomal dominant PKD
(ADPKD) that is typically a late onset disease character-
ized by progressive cyst development and often resulting* Correspondence: harris.peter@mayo.edu
3Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW,
Rochester, MN 55905, USA
Full list of author information is available at the end of the article
© 2013 Vazifehmand et al.; licensee BioMed C
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumin end-stage renal disease (ESRD) [3]. Clinically signifi-
cant extrarenal manifestations include severe polycystic
liver disease and an increased prevalence of intracranial
aneurysms. ADPKD is genetically heterogeneous with
two genes known, PKD1 and PKD2 [4,5]. PKD1 ac-
counts for ~85% of clinical cases and is associated with
more severe disease, with ESRD at 54.3 y compared to
74 y for PKD2 [6]. Recent data from Cornec-Le Gall
also indicated a significance difference in age at ESRD
between PKD1 cases with truncating compared to non-
truncating mutations (55.6 y vs. 67.9 y, respectively) [7].
Diagnostics is usually possible by renal imaging with
specific criteria determined for a positive diagnosis by
ultrasound [8,9], but molecular diagnostic screens can
also be helpful to determine the gene involved and toentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the gene and mutation type can be of prognostic value
(see above), and in rare cases where there is interest, fa-
cilitate preimplantation genetic diagnostics.
The most common recessive form of PKD, autosomal
recessive PKD (ARPKD; incidence 1:20,000), is most
often a neonatal onset disorder and associated with sig-
nificant neonatal demise; although adult presentation of
the disease associated with at least one hypomorphic
allele is increasingly recognized [1,12,13]. A number of
other recessively inherited, syndromic forms of PKD
have additional disease manifestations likely associated
with ciliary dysfunction [2]. These diseases include the
lethal Meckel syndrome, Joubert syndrome, Bardet Biedl
syndrome and orofacial digital syndrome. Extrarenal
manifestations range from liver, eye and digital defects
to central nervous system abnormalities, including men-
tal retardation. These rare disorders are enriched in con-
sanguineous populations.
We describe here a complex Iranian family with mul-
tiple consanguineous relationships that manifests PKD,
but also a number of other abnormalities, including
heart defects, renal agenesis and mental retardation. Mo-
lecular testing of the ADPKD genes identified the mo-
lecular defect; highlighted variability associated with this
mutation, and diagnosed at-risk individuals with negative
or equivocal renal imaging data.Patients and methods
The study was approved by the Ethics Committee at the
Islamic Azad University (8888117001) and the Mayo
Clinic IRB (285–00). Written informed consent was
obtained from all patients for publication of this Case
report. A copy of the written consent is available for
review by the Editor of this journal. Clinical information
was obtained by review of the clinical records and by
interviewing the patients. Clinical data on kidney func-
tion (serum creatinine) and ultrasound imaging data to
determine kidney size, number of cysts and the presence
of renal stones was obtained for at-risk individuals, as
available. The pedigree was drawn employing the Cyrillic
program. Blood samples were collected from 25 family
members for DNA isolation by standard salting out
methods. The genomic DNA of the proband (V:16) was
PCR amplified for all the coding exons of the PKD1 and
PKD2 genes following previously published protocols
[14-16]. Mutation analysis was performed by bidirec-
tional sequencing on PCR-amplified products of all
the coding exons for both the PKD1 and the PKD2
gene. Chromatograms were analyzed using the software
Mutation Surveyor (SoftGenetics Inc.). Segregation ana-
lysis for the detected disease-associated mutation was
performed in all available family members.Case presentation
This family first came to our notice when the proband
(V:16) underwent abdominal ultrasound analysis at 30 y
and a single, large cyst was detected in each kidney. Al-
though these results did not meet the Ravine criteria for
an ADPKD diagnosis, taking a family history revealed
evidence of other family members with renal cystic dis-
ease (Table 1). Careful tracing of the family, plus renal
ultrasound analysis and serum creatinine measurements,
revealed a large family in which 125 individuals could
be traced with at least 30 having some evidence of
renal cystic disease, in four generations (Figure 1). The
family had at least nine consanguineous couples, usually
first cousins, and also cases with mental retardation,
congenital heart disease renal agenesis and early onset
ESRD. Although the consanguinity and range of extra-
renal manifestations (some similar to those found in
ciliopathies) suggested that recessive inheritance may be
important, the PKD seemed to be inherited mainly in a
dominant fashion. We, therefore, screened the ADPKD
genes, PKD1 and PKD2, by sequence analysis for muta-
tions in the proband. This screening revealed a PKD2
deletion, c.1142delG: p.G381fs71X as the only likely dis-
ease causing mutation (Figure 2). Segregation analysis in
the subjects where DNA was available showed that 16
had the PKD2 mutation indicating that this is a PKD2
family. PKD2 is typically a much milder disease than
PKD1 and this is reflected in this family where many
individuals had rather few cysts and normal renal func-
tion (Table 1). Exceptions were IV:20 who had a renal
transplant at 50 y and V:1 who started dialysis at
54 y. Other individuals with marked renal insufficiency
were V:29 with an eGFR of 20 ml/min/1.73 m2 at 54 y,
V:39 with an eGFR of 31 ml/min/1.73 m2 at 38 years and
two older family members with eGFR of 27 (IV:10) and
39 ml/min/1.73 m2 (IV:17) at 75 y and 63 y, respectively.
Several younger individuals shown to inherit the PKD2
mutation had cyst numbers below the threshold for diag-
nosis by ultrasound and in at least one case at 20y (VI:30)
no renal or hepatic cysts were detected. Kidney stones
were commonly found in affected cases and are a known
complication of ADPKD.
A risk in such a consanguineous family is that both
parents will be affected in which case one in four of their
pregnancies would be homozygous for the PKD2 muta-
tion. Pkd2−/− mice are embryonic lethal, dying by 14.5d
of gestation, and it is assumed in humans, but never
proven, that having two fully penetrant PKD2 mutations
is incompatible with life. To further determine the
significance of the PKD2 mutation in this family, we
analyzed a number of family members with unusual
manifestations, including kidney agenesis, early onset
ESRD or other extra-renal manifestations sometimes re-
lated with syndromic PKD, to see if the PKD2 mutant
Table 1 Clinical details of affected cases and others with unusual phenotypes













Right Left Right Left
Affected
III:4 F 56 N/A N/A N/A N/A N/A Dead; PKD N/D
III:8 M 63 N/A N/A N/A N/A N/A Dead; PKD N/D
IV:9 F 67 1.4 113 125 LC 10x6 mm Normal 1142delG
IV:10 F 75 1.8 108 135 Multiple cysts 9 mm stone 1142delG
IV:13 M 77 Dialysis
(75 y)
105 100 LC 22x10 mm 11 mm stone in
middle caulis
Dead; PKD N/D
IV:17 M 63 1.8 118 110 LC 15x8 mm 9 mm stone 1142delG
IV:20 F 53 Tx (50 y) 150 160 Multiple cysts Multiple cysts Dead; PKD N/D
IV:23 M 50 0.9 115 105 4 mm stone LC 15x8 mm N/D
V:1 M 54 Dialysis
(54 y)
N/A N/A N/A N/A Dead; PKD N/D
V:5 M 42 1.1 125 110 LC 15x8 mm 3 mm stone 1142delG
2 mm stone in
middle caulis
V:9 F 38 1.3 100 95 LC 23x18 mm 9 mm stone in
middle caulis
1142delG
3.5 mm stone in
middle caulis
V:14 M 32 0.9 105 105 Multiple cysts Stone 3 mm 1142delG
V:16 (proband) M 30 1.2 105 100 1 cyst, 12x12 mm 1 cyst, 27x22 mm 1142delG
V:22 M 46 1.2 118 110 3 mm stone 1 cyst, 13x13 mm 1142delG
V:24 M 35 0.9 105 107 Normal 2 mm stone 1142delG
V:27 F 49 1.3 108 115 Normal 3.5 mm stone 1142delG
LC 3x3 mm
V:29 F 54 2.5 105 110 1 cyst 10x10 mm 1 cyst, 8x8 mm 1 liver cyst 1142delG
3 mm stone
V:39 F 38 1.8 160 170 Multiple cysts Multiple cysts 1142delG
4.5 mm stone in
interlobular region
V:43 F 37 0.7 112 124 Normal 1 cyst, 13x13 mm 22x23 mm liver cyst 1142delG
VI:5 F 20 0.7 95 90 1.5 mm stone Normal 1142delG
VI:6 F 16 0.7 108 109 Normal 3 mm stone 1142delG
VI:30 F 16 0.8 108 98 Normal Normal 1142delG
PKD suspected
but not proven
IV:15 M 62 0.8 105 100 LC 20x10 mm 9 mm stone in
middle caulis
N/D
3.5 mm stone in
middle caulis
IV:19 F 51 1.5 108 105 1 cyst,
12x8 mm;10 mm
stone
11 mm stone in
middle caulis
N/D
V:10 F 41 1.2 108 105 1 cyst, 10x5 mm Normal N/D
V:19 M 40 1.1 112 108 1 cyst, 6x6 mm Normal N/D
V:25 M 32 0.8 100 105 1 cyst, 6x6 mm Normal N/D
V:26 M 26 0.8 105 100 2 mm stone 1 mm stone N/D
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Table 1 Clinical details of affected cases and others with unusual phenotypes (Continued)













Right Left Right Left
VI:2 F 14 0.8 95 107 Normal 1 cyst, 5x4 mm;
1.5 mm stone
N/D
VI:14 M 24 1.3 107 105 2 mm stone 1 cyst, 7x6 mm N/D
VI:16 M 24 1.7 110 112 Normal 1 cyst, 8X10 mm N/D
VI:17 F 17 0.8 95 95 1 stone Normal N/D
VI:22 M 45 1.4 107 105 1 cyst, 8x5mm 2.6 mm stone N/D
VI:24 M 33 1.1 112 100 1 cyst, 6 mm Normal N/D
Unaffected
V:3 F 53 0.9 105 — Normal Congenitally absent 1142G
V:17 M 39 0.9 110 100 Normal Normal N/D
V:32 F 64 3.59 100 95 43 mm stone,
hydronephrosis
6.7 mm stone 1142G








VI:19 F 34 0.8 95 105 Normal Normal 1142G
VI:20 M 46 0.7 100 105 Normal Normal 1142G
VI:28 M ? N/A N/A N/A N/A N/A Congenital heart disease,
Down syndrome; Dead
N/D
VII:3 M 17 Tx (14y) 85 — No cysts Congenitally absent Reflux Nephropathy 1142G
*LC, largest cyst; ^N/E, not enlarged; N/D, not determined; N/A, not available; + = age last imaging data available.
Vazifehmand et al. BMC Nephrology 2013, 14:190 Page 4 of 6
http://www.biomedcentral.com/1471-2369/14/190allele could be playing a role. IV:17 is affected and sec-
ond cousin to his partner (V:3), who had just a single
kidney, but genetic analysis showed she did not have the
PKD2 mutation. V:40 is married to his affected first
cousin (V:39) and they had two children who died at a
young age (one with Down syndrome and congenital
heart disease), but again the father did not have
the PKD2 mutation. VII:3 had a solitary kidney and
ESRD requiring a renal transplant at 14y, although no
cysts were detected. His maternal grandmother (V:29)
had renal insufficiency due to PKD (Table 1) and large
kidney stones and the paternal grandmother (V:32) had
kidney stones and hydronephrosis. However, genetic
analysis showed that neither of his parents (VI:19
nor VI:20) or the paternal grandmother had the PKD2
mutation, and so the renal failure was not PKD related
and most likely due to reflux nephropathy. The two sibs
with mental retardation (VI:9 and VI:10) are at risk for
PKD2 as the father is affected, but neither had evidence
of cysts at 20y and 16y, respectively. Unfortunately, no
samples were available to test if they had the PKD2
mutation.Conclusions
We describe here an Iranian family with multiple consan-
guinity loops with over 30 individuals with PKD. Despite
the complex structure of the family, by molecular testing
we have been able to show that the PKD is due to a truncat-
ing mutation to PKD2. This firm diagnosis rules out that
syndromic forms of PKD that are enriched in consanguin-
eous populations are playing a role and showed that renal
failure in one child was not related to the PKD2mutation.
Considerable phenotypic variability was seen in the
family both in terms of renal survival, kidney dimensions
and the occurrence of kidney stones. However, it is well
document that there can be considerable intra-familial
variability in ADPKD, indicating that other genetic and
environmental factors significantly influence the pheno-
type [17].
Renal ultrasound and other imaging methods are a
reasonably reliable method to diagnose ADPKD in at-
risk adults. However, ultrasound is less reliable in the
milder PKD2, especially in younger individuals, as illus-
trated in this family with several cases with equivocal
imaging data, showing even with the recent ultrasound
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PKD uncertain: equivocal imaging
Figure 1 Pedigree of the large Iranian family showing the PKD (Affected) and other phenotypes found in the family (see key for
details). The genotype for the PKD2: 1142delG mutation is indicated as N=normal or, d=deleted.
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pecially when state-of-the-art ultrasound equipment is
not employed [8,18]. Molecular diagnostics in ADPKD
requires some considerable effort because of the involve-
ment of the large and complex PKD1 gene, as well as
PKD2, and because of the high level of allelic heterogen-
eity meaning that both genes need to be fully sequenced
to identify the disease gene [10,19]. Commercial testingFigure 2 Sequence chromatograph showing the deletion of G at posi
four Gs that may have contributed to this frame-shifting mutation at this sis therefore expensive. However, this family illustrates
the useful role for molecular diagnostics in ADPKD.
PKD2 was identified as the disease, and once the disease
mutation has been detected the rest of the family can be
readily and inexpensively screened, with unequivocal
diagnostic data obtained. In this family, this has helped
resolve the etiology in some patients with unusual
phenotypes and identified those at risk for developingtion 1142 in exon 5 of the PKD2 gene. Note that the G is in a run of
ite.
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means precious resources can be concentrated on
following these individuals, with prompt treatment of
hypertension, urinary tract infections, kidney stones and
other complications [11]; and not those unaffected.
Although molecular diagnostic is not required in every
suspected ADPKD family it does have a valuable part to
play in some complex families.
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